Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study

妥珠单抗 医学 安慰剂 类风湿性关节炎 内科学 甲氨蝶呤 痹症科 随机对照试验 胃肠病学 关节炎 外科 阿达木单抗 病理 替代医学
作者
Edward Keystone,Désirée van der Heijde,David Mason,Robert Landewé,Ronald van Vollenhoven,Bernard Combe,Paul Emery,Vibeke Strand,Philip J. Mease,Chintu Desai,Karel Pavelká
出处
期刊:Arthritis & Rheumatism [Wiley]
卷期号:58 (11): 3319-3329 被引量:574
标识
DOI:10.1002/art.23964
摘要

Abstract Objective To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti–tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone. Methods In this 52‐week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial, 982 patients were randomized 2:2:1 to receive treatment with subcutaneous certolizumab pegol at an initial dosage of 400 mg given at weeks 0, 2, and 4, with a subsequent dosage of 200 mg or 400 mg given every 2 weeks, plus MTX, or placebo plus MTX. Co‐primary end points were the response rate at week 24 according to the American College of Rheumatology 20% criteria for improvement (ACR20) and the mean change from baseline in the modified total Sharp score at week 52. Results At week 24, ACR20 response rates using nonresponder imputation for the certolizumab pegol 200‐mg and 400‐mg groups were 58.8% and 60.8%, respectively, as compared with 13.6% for the placebo group. Differences in ACR20 response rates versus placebo were significant at week 1 and were sustained to week 52 ( P < 0.001). At week 52, mean radiographic progression from baseline was reduced in patients treated with certolizumab pegol 200 mg (0.4 Sharp units) or 400 mg (0.2 Sharp units) as compared with that in placebo‐treated patients (2.8 Sharp units) ( P < 0.001 by rank analysis). Improvements in all ACR core set of disease activity measures, including physical function, were observed by week 1 with both certolizumab pegol dosage regimens. Most adverse events were mild or moderate. Conclusion Treatment with certolizumab pegol 200 or 400 mg plus MTX resulted in a rapid and sustained reduction in RA signs and symptoms, inhibited the progression of structural joint damage, and improved physical function as compared with placebo plus MTX treatment in RA patients with an incomplete response to MTX.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
漂亮白枫完成签到,获得积分10
刚刚
情怀应助why359采纳,获得10
刚刚
CodeCraft应助wsj采纳,获得10
刚刚
刚刚
领导范儿应助DoctorDiDi采纳,获得10
刚刚
LaTeXer应助勤恳白山采纳,获得80
刚刚
3秒前
小爪冰凉发布了新的文献求助30
3秒前
4秒前
漂亮白枫发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
优雅灵波发布了新的文献求助10
6秒前
kong完成签到,获得积分10
7秒前
7秒前
JJ发布了新的文献求助10
7秒前
幸福大白发布了新的文献求助10
8秒前
9秒前
9秒前
123完成签到,获得积分10
9秒前
Qing完成签到,获得积分10
10秒前
小二郎应助搞笑5次采纳,获得10
10秒前
ZONG发布了新的文献求助20
12秒前
yyyyyyy发布了新的文献求助10
13秒前
勤奋幻柏发布了新的文献求助10
13秒前
why359发布了新的文献求助10
14秒前
14秒前
15秒前
16秒前
hahah完成签到,获得积分10
18秒前
伶俐绿柏发布了新的文献求助10
20秒前
狸宝的小果子完成签到 ,获得积分10
20秒前
汉堡包应助wzc采纳,获得10
20秒前
深情安青应助刀锋采纳,获得10
21秒前
Lc应助古月采纳,获得10
22秒前
why359完成签到,获得积分10
22秒前
22秒前
23秒前
一个醇祝关注了科研通微信公众号
23秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989450
求助须知:如何正确求助?哪些是违规求助? 3531621
关于积分的说明 11254315
捐赠科研通 3270207
什么是DOI,文献DOI怎么找? 1804928
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809176